Chris Simpson and Team Advise Sanacor Inc. on its Collaboration Agreement with Chemify to Develop Small Molecule Therapies for Cardiometabolic Diseases

Polsinelli congratulates its client Sanacor, on its complex collaboration with Chemify to accelerate the development of small-molecule therapies for Cardiometabloic diseases.  

Sanacor Inc. is a biotechnology company developing therapies that target mitochondrial dysfunction in cardiometabolic diseases. The collaboration brings together Chemify’s Chemputation technology for novel, small-molecule design and synthesis with Sanacor’s deep biological expertise in cardiometabolic disease.

The economic terms of the collaboration are confidential and non-public. More information about the collaboration can be obtained here.

The Polsinelli Venture Capital and Emerging Growth Companies team involved in the deal included Chris Simpson and Izzy Drake.